Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Inventory (2019 - 2025)

Harmony Biosciences Holdings' Change in Inventory history spans 7 years, with the latest figure at -$1.5 million for Q4 2025.

  • For Q4 2025, Change in Inventory fell 638.87% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached -$1.8 million, down 200.33%, while the annual FY2025 figure was -$1.8 million, 200.33% down from the prior year.
  • Change in Inventory for Q4 2025 was -$1.5 million at Harmony Biosciences Holdings, down from $782000.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $1.3 million in Q3 2024 and bottomed at -$1.5 million in Q4 2025.
  • The 5-year median for Change in Inventory is $199000.0 (2022), against an average of $76700.0.
  • The largest annual shift saw Change in Inventory skyrocketed 445.92% in 2024 before it crashed 638.87% in 2025.
  • A 5-year view of Change in Inventory shows it stood at -$373000.0 in 2021, then surged by 206.43% to $397000.0 in 2022, then tumbled by 30.48% to $276000.0 in 2023, then grew by 2.54% to $283000.0 in 2024, then plummeted by 638.87% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Change in Inventory are -$1.5 million (Q4 2025), $782000.0 (Q3 2025), and -$284000.0 (Q2 2025).